State NV
Clinical Trials in Nevada
Recruiting clinical trials with at least one study location in Nevada. Data updated daily from ClinicalTrials.gov.
Top Conditions in Nevada
Breast Cancer (5)Chronic Lymphocytic Leukemia (3)Hypertension (3)Asthma (2)Uncontrolled Hypertension (2)Small Lymphocytic Lymphoma (2)Schizophrenia (2)Geographic Atrophy (2)Acupuncture (2)Parkinson Disease (2)Non-small Cell Lung Cancer (1)Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)
Frequently Asked Questions — Clinical Trials in Nevada
How many clinical trials are currently recruiting in Nevada?
ClinicalMetric currently tracks 86 actively recruiting clinical trials with at least one location in Nevada. The total number of registered studies—including active but not currently enrolling trials—is 86. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in Nevada?
Nevada hosts clinical trials across a broad range of medical conditions, including Breast Cancer, Chronic Lymphocytic Leukemia, Hypertension, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout Nevada serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in Nevada?
To join a clinical trial in Nevada, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in Nevada maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in Nevada
NCT06635148 Phase 2
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Part...
Condition
Geographic Atrophy
Enrollment
274 pts
Location
United States, Australia, Belgium
Sponsor
Janssen Research & Development
NCT06291376 Phase 3
Recruiting
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Condition
Immunoglobulin A Nephropathy
Enrollment
510 pts
Location
United States, Argentina, Australia
Sponsor
Alexion Pharmaceuticals, Inc.
NCT07211178 N/A
Recruiting
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor...
Condition
Breast Cancer
Enrollment
900 pts
Location
United States
Sponsor
Tempus AI
NCT06689085 Phase 3
Recruiting
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTE...
Condition
Hypogonadism, Male
Enrollment
100 pts
Location
United States
Sponsor
Halozyme Therapeutics
NCT06958328 Phase 3
Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Condition
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma
Enrollment
356 pts
Location
United States
Sponsor
NRG Oncology
NCT06384352 Phase 1
Recruiting
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Effic...
Condition
Advanced Solid Tumors
Enrollment
155 pts
Location
United States, Australia, Canada
Sponsor
MediLink Therapeutics (Suzhou)
NCT05615844 Phase 3
Recruiting
Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy
Condition
Open tíbia Fracture
Enrollment
312 pts
Location
United States, Canada
Sponsor
University of Maryland, Baltim
NCT04852887 Phase 3
Recruiting
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, O...
Condition
Stage I Breast Cancer
Enrollment
1,670 pts
Location
United States, Canada, Hong Kong
Sponsor
NRG Oncology
NCT06401044 Phase 1, Phase 2
Recruiting
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Dis...
Condition
Thyroid Eye Disease
Enrollment
88 pts
Location
United States, Australia, Canada
Sponsor
Amgen
NCT06813911 Phase 3
Recruiting
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Partic...
Condition
Atherosclerotic Cardiovascular Disease (ASCVD)
Enrollment
340 pts
Location
United States, China, France
Sponsor
Novartis Pharmaceuticals
NCT07441252 Phase 2
Recruiting
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Liv...
Condition
Overweight or Obesity and Elevated Liver Fat
Enrollment
180 pts
Location
United States
Sponsor
Amgen
NCT05504499 N/A
Recruiting
REFINE Study: A Study In a Novel Interspinous Fusion Device In Subjects With Low...
Condition
Lumbar Spinal Stenosis
Enrollment
100 pts
Location
United States
Sponsor
Pacific Research Institute
NCT04477785 N/A
Recruiting
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
Condition
Parkinson Disease
Enrollment
4,500 pts
Location
United States, Austria, Canada
Sponsor
Michael J. Fox Foundation for
NCT07428499 Phase 3
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (H...
Condition
Hereditary Angioedema (HAE)
Enrollment
90 pts
Location
United States, Argentina, Australia
Sponsor
ADARx Pharmaceuticals, Inc.
NCT05762107 Phase 2
Recruiting
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Condition
Type 1 Diabetes Mellitus With Hypoglycemia
Enrollment
186 pts
Location
United States, Canada
Sponsor
Zucara Therapeutics Inc.
NCT06585410 Phase 3
Recruiting
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous S...
Condition
Cutaneous Squamous Cell Carcinoma (CSCC)
Enrollment
369 pts
Location
United States, Australia
Sponsor
Regeneron Pharmaceuticals
NCT06419374 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With...
Condition
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Enrollment
762 pts
Location
United States, Argentina, Australia
Sponsor
89bio, Inc.
NCT06283966 Phase 3
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fum...
Condition
COPD (Chronic Obstructive Pulmonary Disease)
Enrollment
5,000 pts
Location
United States, Argentina, Australia
Sponsor
AstraZeneca
NCT07009860 Phase 2
Recruiting
RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide...
Condition
Alcohol Liver Disease
Enrollment
100 pts
Location
United States, Puerto Rico
Sponsor
Altimmune, Inc.
NCT06029439 Phase 3
Recruiting
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Condition
Major Depressive Disorder
Enrollment
1,000 pts
Location
United States, Brazil, Bulgaria
Sponsor
Neumora Therapeutics, Inc.
NCT07502495 Phase 2
Recruiting
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Ach...
Condition
Type 2 Diabetes
Enrollment
60 pts
Location
United States
Sponsor
Biomea Fusion Inc.
NCT06659445 Phase 2
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated ...
Condition
Geographic Atrophy (GA)
Enrollment
324 pts
Location
United States, Canada
Sponsor
ONL Therapeutics
NCT05561114 Phase 3
Recruiting
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophag...
Condition
Esophageal Stricture
Enrollment
198 pts
Location
United States
Sponsor
GIE Medical
NCT04028687 N/A
Recruiting
MDR - PMCF Study for Taperloc Complete Stems
Condition
Hip Arthritis
Enrollment
820 pts
Location
United States
Sponsor
Zimmer Biomet
NCT05787587 Phase 1
Recruiting
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Condition
Advanced or Metastatic Solid Tumors
Enrollment
216 pts
Location
United States
Sponsor
IDEAYA Biosciences
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology